Literature DB >> 16507216

VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.

Brian I Rini1.   

Abstract

Several molecular pathways are implicated in renal cell carcinoma (RCC) pathogenesis, including von Hippel--Lindau (VHL) gene inactivation leading to vascular endothelial growth factor (VEGF) expression. Therapeutic targeting of VEGF and related pathways has been undertaken in metastatic RCC. Substantial clinical activity has been reported for multiple agents, leading to several clinical questions regarding the optimal use of these agents. The biology, clinical results, and future considerations regarding VEGF-targeted agents in RCC are presented in this article.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16507216     DOI： 10.1007/s11912-006-0041-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  32 in total

1.  Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.

Authors:  Li Sun; Chris Liang; Sheri Shirazian; Yong Zhou; Todd Miller; Jean Cui; Juri Y Fukuda; Ji-Yu Chu; Asaad Nematalla; Xueyan Wang; Hui Chen; Anand Sistla; Tony C Luu; Flora Tang; James Wei; Cho Tang
Journal:  J Med Chem       Date:  2003-03-27       Impact factor: 7.446

2.  Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells.

Authors:  Y Watanabe; S W Lee; M Detmar; I Ajioka; H F Dvorak
Journal:  Oncogene       Date:  1997-05-01       Impact factor: 9.867

Review 3.  Discovery of a novel Raf kinase inhibitor.

Authors:  J F Lyons; S Wilhelm; B Hibner; G Bollag
Journal:  Endocr Relat Cancer       Date:  2001-09       Impact factor: 5.678

Review 4.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.

Authors:  Daniel J Hicklin; Lee M Ellis
Journal:  J Clin Oncol       Date:  2004-12-07       Impact factor: 44.544

5.  Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor.

Authors:  R K Jain; N Safabakhsh; A Sckell; Y Chen; P Jiang; L Benjamin; F Yuan; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

6.  Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.

Authors:  Beverly Drucker; Jennifer Bacik; Michelle Ginsberg; Stephanie Marion; Paul Russo; Madhu Mazumdar; Robert Motzer
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

Review 7.  Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis.

Authors:  J R Gnarra; M I Lerman; B Zbar; W M Linehan
Journal:  Semin Oncol       Date:  1995-02       Impact factor: 4.929

8.  Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.

Authors:  Tetsuichiro Inai; Michael Mancuso; Hiroya Hashizume; Fabienne Baffert; Amy Haskell; Peter Baluk; Dana D Hu-Lowe; David R Shalinsky; Gavin Thurston; George D Yancopoulos; Donald M McDonald
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

9.  Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.

Authors:  L E Benjamin; D Golijanin; A Itin; D Pode; E Keshet
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

10.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.